ProQR Therapeutics (NASDAQ:PRQR), a Leiden, Netherlands-based clinical-stage biotechnology company developing RNA-based therapies for severe genetic rare diseases, on Thursday reported a net loss of $9.1 million for its fourth quarter ended December 31, 2025.
The company said it had a loss of 9 cents per share.
The results missed the average estimate of an 8-cent loss per share from three analysts surveyed by Zacks Investment Research.
Revenue for the period totaled $5.5 million, primarily from collaboration agreements and license-related income tied to its ophthalmology programs.
For the full year 2025, ProQR reported a net loss of $47.7 million, or 45 cents per share.
Revenue reached $18 million, reflecting contributions from ongoing partnerships and milestone payments as the company advanced its pipeline of intravitreal RNA therapies targeting inherited retinal diseases.